Mar 31, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
Mar 30, 2022
The total capital represents the largest seed financing for life science startups in Utah's history SALT LAKE CITY, March 30, 2022 /PRNewswire/ -- Altitude Lab today announced its first cohort of...
Mar 24, 2022
Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on...
- Mar 23, 2022Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40...
Mar 18, 2022Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular...